$241,000 of GUARDANT HEALTH lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"precision diagnostics and preventive screening innovation precision diagnostics, cancer care, and preventive screening innovation"
You can find more data on corporate lobbying on Quiver Quantitative.
GH Insider Trading Activity
GH insiders have traded $GH stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:
- AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 12 sales selling 340,000 shares for an estimated $16,998,565.
- KUMUD KALIA (Chief Information Officer) has made 0 purchases and 2 sales selling 7,500 shares for an estimated $336,621.
- IAN T CLARK sold 6,672 shares for an estimated $322,818
- MUSA TARIQ has made 0 purchases and 5 sales selling 3,677 shares for an estimated $179,984.
- MEGHAN V. JOYCE has made 0 purchases and 3 sales selling 3,537 shares for an estimated $166,010.
- MYRTLE S POTTER has made 0 purchases and 3 sales selling 2,678 shares for an estimated $133,051.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GH Hedge Fund Activity
We have seen 167 institutional investors add shares of GH stock to their portfolio, and 161 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 2,855,482 shares (-58.9%) from their portfolio in Q1 2025, for an estimated $121,643,533
- CITADEL ADVISORS LLC added 2,115,024 shares (+142.7%) to their portfolio in Q1 2025, for an estimated $90,100,022
- FIL LTD removed 1,943,061 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $82,774,398
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,933,086 shares (+inf%) to their portfolio in Q1 2025, for an estimated $82,349,463
- BRAIDWELL LP removed 1,520,604 shares (-53.4%) from their portfolio in Q1 2025, for an estimated $64,777,730
- INVESCO LTD. added 1,403,670 shares (+100.9%) to their portfolio in Q1 2025, for an estimated $59,796,342
- DEEP TRACK CAPITAL, LP removed 975,845 shares (-15.2%) from their portfolio in Q1 2025, for an estimated $41,570,997
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GH Analyst Ratings
Wall Street analysts have issued reports on $GH in the last several months. We have seen 14 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 06/13/2025
- Piper Sandler issued a "Overweight" rating on 05/06/2025
- Scotiabank issued a "Sector Outperform" rating on 05/05/2025
- Canaccord Genuity issued a "Buy" rating on 05/01/2025
- Stifel issued a "Buy" rating on 05/01/2025
- Barclays issued a "Overweight" rating on 05/01/2025
- TD Securities issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for GH, check out Quiver Quantitative's $GH forecast page.
GH Price Targets
Multiple analysts have issued price targets for $GH recently. We have seen 14 analysts offer price targets for $GH in the last 6 months, with a median target of $59.5.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $65.0 on 06/13/2025
- David Westenberg from Piper Sandler set a target price of $60.0 on 05/06/2025
- Sung Ji Nam from Scotiabank set a target price of $57.0 on 05/05/2025
- Dan Brennan from TD Securities set a target price of $60.0 on 05/01/2025
- Daniel Arias from Stifel set a target price of $60.0 on 05/01/2025
- Kyle Mikson from Canaccord Genuity set a target price of $65.0 on 05/01/2025
- Luke Sergott from Barclays set a target price of $60.0 on 05/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
